Achillion shares soar as potential treatment seen as hep C cure

December 22, 2014 12:56 PM

15 0

(Reuters) - Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.

The biotechnology company's shares shot up about 60 percent to $22.76 in premarket trading on Monday.

Read more

To category page